SHORT HILLS, N.J.--(BUSINESS WIRE)--Speaking to shareholders at the Zoetis Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix discussed the company’s strong performance over the past five years and strategies for continued growth as the leader in the global animal health industry.
“In 2017, we delivered our fifth consecutive year of operational revenue growth and increased profitability based on deep relationships with customers, innovative research and development, and high-quality manufacturing and supply,” said Alaix. “As we look to the future, we are energized by the growth opportunities in animal health that will keep us on the path of continued industry leadership, and we remain firmly committed to delivering on the long-term value proposition that has generated returns for our investors.”
Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. Preliminary results of shareholder voting from the meeting are as follows:
- Sanjay Khosla, Willie M. Reed, Linda Rhodes and William C. Steere, Jr. have been elected as directors for three-year terms.
- Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers.
- Shareholders ratified and approved the selection of KPMG LLP as the company’s independent registered public accounting firm for fiscal year 2018.
The final results of the shareholder voting are subject to verification by the independent election inspector; results will be filed in a Form 8-K and available on the Investor section of the Zoetis website.
A full replay of the meeting will be made available at http://investor.zoetis.com/events-presentations, along with the presentation materials from the event.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
